BiotechTube

LDK378 + AUY922

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anaplastic Lymphoma Kinase (ALK)

Conditions

Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer

Trial Timeline

Jun 1, 2013 → Jan 1, 2016

NCT ID
NCT01772797

About LDK378 + AUY922

LDK378 + AUY922 is a phase 1 stage product being developed by Novartis for Anaplastic Lymphoma Kinase (ALK). The current trial status is completed. This product is registered under clinical trial identifier NCT01772797. Target conditions include Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer.

What happened to similar drugs?

0 of 1 similar drugs in Anaplastic Lymphoma Kinase (ALK) were approved

Approved (0) Terminated (0) Active (1)
🔄Alectinib + CrizotinibRochePhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01772797Phase 1Completed

Competing Products

20 competing products in Anaplastic Lymphoma Kinase (ALK)

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
24
efatutazone + paclitaxelDaiichi SankyoPhase 2
35
Lenvatinib 24 mgEisaiPhase 2
27
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
39
durvalumab + tremelimumabAstraZenecaPhase 1
29
PembrolizumabMerckPhase 2
35
ceritinibNovartisPre-clinical
30
LDK378NovartisPhase 1
29
CeritinibNovartisPhase 2
27
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastimNovartisPhase 1
29
dabrafenib/trametinibNovartisPhase 2
42
Trametinib + PaclitaxelNovartisPhase 1
33
Alectinib + CrizotinibRochePhase 3
44
Sunitinib MalatePfizerPhase 2
35
Crizotinib (PF-02341066)PfizerPhase 2
35
LorlatinibPfizerPhase 2
31
CrizotinibPfizerPhase 1/2
32
Cemiplimab + XL092Regeneron PharmaceuticalsPhase 1
36
Etirinotecan pegolNektar TherapeuticsPhase 2
29
BevacizumabNovocurePhase 2
36